Stephen Kent to Australia
This is a "connection" page, showing publications Stephen Kent has written about Australia.
Connection Strength
0.421
-
Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine. 2017 11 07; 35(47):6451-6458.
Score: 0.133
-
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster. EBioMedicine. 2023 Dec; 98:104878.
Score: 0.051
-
Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19. Immunol Cell Biol. 2023 Nov-Dec; 101(10):964-974.
Score: 0.050
-
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat Immunol. 2023 06; 24(6):966-978.
Score: 0.049
-
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine. EBioMedicine. 2023 Jun; 92:104574.
Score: 0.049
-
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec; 74:103729.
Score: 0.044
-
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proc Natl Acad Sci U S A. 2021 10 12; 118(41).
Score: 0.044